Cyclo Therapeutics (NASDAQ:CYTH) Trading 1.4% Higher – Should You Buy?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) shares traded up 1.4% during mid-day trading on Friday . The stock traded as high as $0.85 and last traded at $0.82. 33,205 shares traded hands during trading, a decline of 37% from the average session volume of 52,627 shares. The stock had previously closed at $0.81.

Cyclo Therapeutics Price Performance

The firm has a 50-day moving average of $0.67 and a 200 day moving average of $0.81. The stock has a market capitalization of $23.62 million, a price-to-earnings ratio of -0.91 and a beta of -0.49.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.